Based on the aggregated intelligence of 125,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical lab operator Quest Diagnostics (NYSE:DGX) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Quest Diagnostics' business and see what CAPS investors are saying about the stock right now.

Quest Diagnostics facts

Headquarters (founded)

Madison, New Jersey (1967)

Market Cap

$9.75 billion

Industry

Health Care Services

TTM Revenue

$7.25 billion

Management

Chairman/CEO Dr. Surya Mohapatra

CFO Robert Hagemann

Competitors

LabCorp (NYSE:LH),

Bio-Reference Labs (NASDAQ:BRLI)

CAPS members bullish on DGX also bullish on:

Johnson & Johnson (NYSE:JNJ),

General Electric (NYSE:GE)

CAPS members bearish on DGX also bearish on:

Morgan Stanley (NYSE:MS),

Garmin (NASDAQ:GRMN)

Sources: Capital IQ (a division of Standard & Poor's), and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 479 of the 502 members who have rated Quest Diagnostics -- some 95% -- believe the stock will outperform the S&P 500 going forward. These bulls include paintjockey and samhanlj.

In December, paintjockey came at Quest from a consumer perspective: "Growth is slow but steady. I use this service as a patient. Neither too pricy or cheap on service. Product is stable with elderly population growing, services a plus for medical community."

In a pitch from late last month, samhanlj expands on the unfortunately real trend working in the industry's favor:

A sure thing coming up right behind death and taxes: illness. As one of the biggest lab/diagnostic services in the country, Quest has solid earnings and dividends and an 8% NET profit margin. Not too shabby. Having said all this, I'd also have to recommend their biggest competitor, [LabCorp], whose financials look even stronger.

What do you think about Quest Diagnostics, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 125,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Quest Diagnostics is a Motley Fool Inside Value pick, LabCorp is a Stock Advisor choice, Johnson & Johnson is an Income Investor selection, and Garmin is a recommendation of Global Gains. The Fool's disclosure policy always gets a perfect score.